Imagion Biosystems (ASX:IBX)
We talked with Bob Proulx, Executive Chairman of Imagion Biosystems, about the company’s progress with MagSense. Imagion now has data on the clinical utility of MagSense in detecting metastases in Her-2 positive breast cancer. The company is now recapitalised and getting ready for a Phase 2 study.
Check out our research on Imagion Biosystems here!
Disclosure: Imagion Biosystems is a research client of Pitt Street Research and our directors own IBX shares.
Looking for the Best ASX Life Sciences stocks to invest in right now?
